MX2021001089A - Borato de derivado de azetidina. - Google Patents

Borato de derivado de azetidina.

Info

Publication number
MX2021001089A
MX2021001089A MX2021001089A MX2021001089A MX2021001089A MX 2021001089 A MX2021001089 A MX 2021001089A MX 2021001089 A MX2021001089 A MX 2021001089A MX 2021001089 A MX2021001089 A MX 2021001089A MX 2021001089 A MX2021001089 A MX 2021001089A
Authority
MX
Mexico
Prior art keywords
borate
azetidine derivative
azetidine
derivative
tautomer
Prior art date
Application number
MX2021001089A
Other languages
English (en)
Inventor
Jian Xiong
Cheng Xie
Xiongbin Xu
Jian Li
Shuhui Chen
Aiming Zhang
Xiquan Zhang
Xin Tian
CHEN Kevin X
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2021001089A publication Critical patent/MX2021001089A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto borato de un derivado de azetidina, que se refiere en particular a un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo, un tautómero del mismo, un estereoisómero del mismo o un isómero geométrico del mismo, así como su uso en la preparación de un medicamento que se usa para el tratamiento o la prevención del mieloma múltiple. (ver Fórmula).
MX2021001089A 2018-08-02 2019-08-02 Borato de derivado de azetidina. MX2021001089A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810872672 2018-08-02
CN201810989128 2018-08-28
PCT/CN2019/098990 WO2020025037A1 (zh) 2018-08-02 2019-08-02 氮杂环丁烷衍生物的硼酸酯

Publications (1)

Publication Number Publication Date
MX2021001089A true MX2021001089A (es) 2021-05-12

Family

ID=69232369

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001089A MX2021001089A (es) 2018-08-02 2019-08-02 Borato de derivado de azetidina.

Country Status (15)

Country Link
US (1) US11466036B2 (es)
EP (1) EP3831834A4 (es)
JP (1) JP7434273B2 (es)
KR (1) KR20210040109A (es)
CN (2) CN115772188A (es)
AU (1) AU2019315561B2 (es)
BR (1) BR112021001963B1 (es)
CA (1) CA3107925A1 (es)
IL (1) IL280489B1 (es)
MX (1) MX2021001089A (es)
PH (1) PH12021550248A1 (es)
SG (1) SG11202100907TA (es)
TW (1) TWI810344B (es)
WO (1) WO2020025037A1 (es)
ZA (1) ZA202100661B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198060A1 (zh) * 2022-04-12 2023-10-19 正大天晴药业集团股份有限公司 蛋白酶体抑制剂与抗pd-1抗体的药物组合

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EA201500431A1 (ru) 2008-06-17 2015-11-30 Милленниум Фармасьютикалз, Инк. Соединения боронатного эфира и его фармацевтические составы
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
US20140121182A1 (en) * 2011-06-22 2014-05-01 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
AU2012301810B2 (en) 2011-08-30 2017-06-01 Trustees Of Tufts College FAP-activated proteasome inhibitors for treating solid tumors
CN105732683B (zh) * 2016-03-25 2018-10-16 南京林业大学 一类羧酸与α氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
TW201831191A (zh) 2017-01-23 2018-09-01 大陸商成都奥璟生物科技有限公司 一種新的硼酸衍生物及其藥物組合物
MX2019010108A (es) * 2017-02-28 2020-01-13 Chia Tai Tianqing Pharmaceutical Group Co Ltd Derivados de azetidina.

Also Published As

Publication number Publication date
EP3831834A1 (en) 2021-06-09
IL280489B1 (en) 2024-02-01
CN112513052B (zh) 2022-12-16
KR20210040109A (ko) 2021-04-12
SG11202100907TA (en) 2021-03-30
TWI810344B (zh) 2023-08-01
JP2021531302A (ja) 2021-11-18
ZA202100661B (en) 2023-08-30
CN112513052A (zh) 2021-03-16
US20210163507A1 (en) 2021-06-03
US11466036B2 (en) 2022-10-11
EP3831834A4 (en) 2021-10-27
PH12021550248A1 (en) 2021-11-03
CA3107925A1 (en) 2020-02-06
JP7434273B2 (ja) 2024-02-20
CN115772188A (zh) 2023-03-10
IL280489A (en) 2021-03-25
BR112021001963A2 (pt) 2021-04-27
AU2019315561B2 (en) 2024-01-25
TW202007690A (zh) 2020-02-16
BR112021001963B1 (pt) 2024-02-15
WO2020025037A1 (zh) 2020-02-06
AU2019315561A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
TN2015000034A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
EP4316591A3 (en) Oxysterols and methods of use thereof
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EA202193015A1 (ru) Ингибиторы cdk
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
PH12019550154A1 (en) Azetidine derivative
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2021007140A (es) Compuesto para usarse en enfermedades de la retina.
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
PH12021550248A1 (en) Borate of azetidine derivative
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2021007258A (es) Composiciones de esparsentan amorfas.
SG11201803867TA (en) Sodium channel blocker
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
MX2022001044A (es) Inhibidor de sglt2/dpp4 y su aplicacion.
PH12020550549A1 (en) Compositions for preventing or treating lupus
MX2018015990A (es) Compuestos terapeuticos.
EA201991932A1 (ru) Производное азитидина